Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Cabel L, Lamy C, Keough K, Abbott C, Pouget N, Pierga J, Sablin M, Flavius J, Bronzini T, Laas E, Darrigues L, Feron J, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S, Chen R, Le Tourneau C, Bidard F. Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2025, 43: 552-552. DOI: 10.1200/jco.2025.43.16_suppl.552.Peer-Reviewed Original ResearchTriple-negative breast cancerPathological complete responsePost-NACCtDNA detectionFollow-upPlasma ctDNADistant metastasisDistant relapse-free intervalPathological complete response statusPatients treated with NACTriple-negative breast cancer patientsEarly-stage TNBC patientsPost-surgical follow-upCtDNA-negative patientsCtDNA-positive patientsPost-neoadjuvant chemotherapyResidual disease levelsStratify survival outcomesImmune checkpoint inhibitorsNon-relapsing patientsRelapse-free intervalAdjuvant treatment decisionsMedian Follow-UpTumor-specific variantsMultivariate Cox model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply